Home » Stocks » MCRB

Seres Therapeutics, Inc. (MCRB)

Stock Price: $20.73 USD -1.26 (-5.73%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $20.01 -0.72 (-3.47%) May 7, 4:15 PM
Market Cap 1.90B
Revenue (ttm) 30.74M
Net Income (ttm) -104.71M
Shares Out 91.53M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $20.73
Previous Close $21.99
Change ($) -1.26
Change (%) -5.73%
Day's Open 22.65
Day's Range 20.55 - 23.46
Day's Volume 931,060
52-Week Range 3.67 - 38.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -18.18% and 7.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

Shares of Seres Therapeutics (NASDAQ:MCRB) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 39.29% year over year to ($0.39), which missed the estimat...

4 days ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally inte...

4 days ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast o...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Ther...

3 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppe...

1 month ago - Business Wire

Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma. The company cited challenges...

1 month ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company, in collaboration with study partners, The Parker Institute for Cancer Immunotherapy (PICI) an...

2 months ago - Business Wire

With the trading day about halfway over, the broad markets pushed lower after a decent start to the day.

Other stocks mentioned: BA, CSCO, NKLA, ORCL, NIU, PETS, QMCO
2 months ago - 24/7 Wall Street

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 30.77% and 99.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided bu...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company has achieved target enrollment of the Phase 2b ECO-RESET clinical study of SER-287 in patients...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferen...

2 months ago - Business Wire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, DNLI, EVLO, FHTX, KLDO, MRNA ...
2 months ago - PRNewsWire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to function...

2 months ago - Business Wire

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--New data from microbiome and metabolomic endpoints provide mechanistic support of Seres' positive Phase 3 results in recurrent C. difficile infection.

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, Jan...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company's Phase 1b trial of SER-287 in patients with active mild-to-m...

4 months ago - Business Wire

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: CRSP, DNLI, NK, RCKT
4 months ago - Zacks Investment Research

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

Other stocks mentioned: BNTX, CLDX, CODX, CRDF, MRNA, NSRGY, NVAX ...
4 months ago - The Motley Fool

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

Other stocks mentioned: INO, NVAX, PFE, TWST
4 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Health...

5 months ago - Business Wire

Late August spike means share price moves from below $5 to more than $30. Capital raising and Nestle agreement raised $264 million.

5 months ago - Seeking Alpha

Seres has seen +863% upside YTD on the back of positive top-line data in their phase 3 SER-109 study, which helps prove their microbiome hypotheses. Management have strengthened the cash position and th...

5 months ago - Seeking Alpha

Seres has appreciated over 800% in the last one year. Despite strong phase 3 efficacy data, the FDA has asked for additional safety data.

5 months ago - Seeking Alpha

Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -50.00% and -84.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB) today reported financial results from the third quarter ended September 30, 2020, and provided business updates. “Supported by...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild-t...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to function...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President,...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the presentation of previously announced positive Phase 3 results from the ECOSPOR III trial of SER-109 at the ...

6 months ago - Business Wire

The tech-heavy Nasdaq index posted its best third quarter in 10 years this year.

Other stocks mentioned: AUTO, ONEQ, QQQ, QQQE, SUNW
7 months ago - Zacks Investment Research

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: ADAP, CCXI, KOD, MYOV, NVAX, SRNE
7 months ago - InvestorPlace

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Next Generation IBD Therapeutics Summit on Wednesday...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

7 months ago - Business Wire

A small Boston-area biotech hopes to usher in a new era in disease treatment by getting regulatory approval for its microbiome drug.

8 months ago - GuruFocus

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--Seres Therapeutics, Inc.

8 months ago - Business Wire

A major investor boosted its stake in the microbiome therapeutics leader.

8 months ago - The Motley Fool

Seres Therapeutics stock slipped early Thursday after the small biotech priced and boosted the size of a stock offering two days after its positive drug trial news sent MCRB stock soaring. The post Tin...

8 months ago - Investors Business Daily

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc.

8 months ago - Business Wire

A Relative Strength Rating upgrade for Seres Therapeutics shows improving technical performance. The post Stocks With Rising Relative Price Strength: Seres Therapeutics appeared first on Investor's Busi...

8 months ago - Investors Business Daily

The company's new dug could be a game changer.

8 months ago - The Motley Fool

Shares of the small-cap biopharma Seres Therapeutics Inc (NASDAQ: MCRB) were ripping higher Monday.

8 months ago - Benzinga

Seres Therapeutics Inc. (NASDAQ: MCRB) shares more than tripled early on Monday after the firm announced positive late-stage results for its C.

8 months ago - 24/7 Wall Street

Shares of Seres Therapeutics Inc. MCRB, +4.74% rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phas...

8 months ago - Market Watch

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MCRB--SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C.

8 months ago - Business Wire

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use wit... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2015
CEO
Eric Shaff
Employees
155
Stock Exchange
NASDAQ
Ticker Symbol
MCRB
Full Company Profile

Financial Performance

In 2020, MCRB's revenue was $33.22 million, a decrease of -3.74% compared to the previous year's $34.51 million. Losses were -$89.13 million, 26.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is 38.00, which is an increase of 83.31% from the latest price.

Price Target
$38.00
(83.31% upside)
Analyst Consensus: Buy